Nurix Therapeutics announced that the U.S. Food and Drug Administration FDA has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. Screening and enrollment of new study participants has been paused. Patients currently enrolled in the clinical study who are deriving clinical benefit may continue to receive treatment in accordance with the ongoing study protocol. Nurix is working with the FDA to resolve the partial clinical hold as soon as possible. The partial clinical hold follows the company’s communication to the FDA of its intention to transition to an improved manufacturing process. Nurix’s other drug programs are not affected by the NX-2127 manufacturing process improvement. “The initial NX-2127 manufacturing process produced a Phase 1 drug product that has yielded important proof-of-concept results with meaningful clinical responses in patients with advanced B-cell malignancies,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “While the partial hold is in effect, we will supply the current drug product for patients who continue on therapy in the Phase 1 study and will work expeditiously with FDA to introduce the improved NX-2127 manufacturing process and drug product into our clinical development plan.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
- Cathie Wood’s ARK Investment bought 140K shares of Nurix Therapeutics today
- Nurix Therapeutics price target lowered to $24 from $31 at Baird
- Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update